Floatz logo

Immunoglobulin G1 [de-236-glycine,267-glutamic acid,de-C-terminal lysine], anti-(human tumor necrosis factor receptor TNFRSF9) (human-Mus musculus monoclonal LVGN6051 ?1-chain), disulfide with human-Mus musculus monoclonal LVGN6051 ?-chain, dimer

Metastatic Esophageal

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

130 Active assets in the Metastatic Esophageal cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 4BB
Benadryl
Ciusss de L'Est de l'Île de Montréal
Phase 3B
Pembrolizumab
Essen Biotech
Phase 3B
Cyclophosphamide
Sutro Biopharma, Inc.
Phase 3B

View all 50 →

Same molecule, other indications

Immunoglobulin G1 [de-236-glycine,267-glutamic acid,de-C-terminal lysine], anti-(human tumor necrosis factor receptor TNFRSF9) (human-Mus musculus monoclonal LVGN6051 ?1-chain), disulfide with human-Mus musculus monoclonal LVGN6051 ?-chain, dimer is also rated in:

head and neck carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
Metastatic HPV Related Solid TumorsDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →